Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported equity awards of company common stock. On February 18, 2026, he acquired 7,690 shares of restricted stock at
The filing notes that 1,430 shares were issued upon satisfaction of performance criteria from a performance share unit award granted on
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported acquiring company stock through equity awards. On February 18, 2026, he received 10,254 shares of Encompass Health common stock at a price of $0.00 per share as a grant or award, bringing his direct holdings to 26,296 shares.
On February 19, 2026, he received an additional 3,790 restricted shares at $0.00 per share, increasing his direct ownership to 30,086 shares. Footnotes state that one issuance reflects satisfaction of performance criteria from a February 23, 2023 performance share unit award, and the other is an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp. President & CEO Mark J. Tarr, who is also a director, reported multiple open-market sales of company common stock on February 11, 2026.
He sold a total of 150,000 shares at weighted-average prices ranging from $107.47 to $113.58 per share, and directly owned 377,070 shares of Encompass Health common stock after these transactions.
Invesco Ltd. has reported a significant shareholding in Encompass Health Corp. As of 12/31/2025, Invesco, as a parent holding company to its investment advisers, may be deemed to beneficially own 4,972,725 shares of Encompass Health common stock, representing 4.9% of the class.
Invesco has sole voting power over 4,761,846 shares and sole dispositive power over 4,972,725 shares, with no shared voting or dispositive power. The shares are held of record by clients of Invesco’s advisers, and no single individual has more than 5% economic ownership.
Invesco certifies that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Encompass Health, consistent with a passive investment reported on a Schedule 13G/A.
Encompass Health Corporation has a planned sale of restricted or control securities under Rule 144. The notice covers up to 150000 shares of common stock, with an aggregate market value of 16738961, to be sold through UBS Financial Services Inc. on the NYSE.
The filing states that 100615977 shares of the issuer’s common stock are outstanding. It also shows an acquisition entry where common stock was acquired on 02/17/2020 via RSA vesting from Encompass Health Corporation, with 2514 securities in that transaction.
Encompass Health Corp. executive vice president and chief operating officer Patrick William Tuer sold 2,804 shares of Encompass Health common stock in an open market transaction on February 10, 2026. The shares were sold at a weighted average price of $107.62 per share, in multiple trades ranging from $107.55 to $107.73. Following this sale, Tuer directly beneficially owns 16,042 shares of Encompass Health common stock.
Encompass Health Corporation has a shareholder filing a notice to sell 2,804 shares of its common stock under Rule 144. The planned sale through UBS Financial Services Inc. is listed with an aggregate market value of 301755, with trading on the NYSE around 02/10/2026.
The shares to be sold were acquired from Encompass Health Corporation through restricted stock unit vesting on 02/23/2024 and 02/24/2024, and performance stock unit vesting on 01/01/2025. Shares outstanding were 100,615,977 common shares at the time referenced.
Encompass Health Corporation filed a Form 8‑K to furnish its financial results for the three months and year ended December 31, 2025, as disclosed in a press release (Exhibit 99.1) and supplemental earnings materials (Exhibit 99.2).
The company explains its use of same‑store comparisons, which include hospitals open in both periods and incorporate market consolidations and capacity expansions where isolating incremental impact is difficult. It also highlights several non‑GAAP measures: adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
Encompass Health describes how Adjusted EBITDA and its leverage ratio are central to covenants in its credit agreement, affecting the ability to incur debt, pay dividends, and make certain investments. The filing also outlines the company’s definition of adjusted free cash flow and includes extensive cautionary language about forward‑looking statements tied to its strategy, growth targets, capital plans, and financial outlook.
Encompass Health Corporation reported that its Board of Directors elected Cain A. Hayes as a director on January 30, 2026, following a recommendation from its Nominating/Corporate Governance Committee. The Board has determined that Mr. Hayes is independent under New York Stock Exchange listing standards and the company’s Corporate Governance Guidelines.
Mr. Hayes will receive compensation consistent with the company’s standard practices for nonemployee directors, as described in its April 1, 2025 proxy statement. The company stated there are no arrangements or understandings with other persons related to his selection and no related party transactions involving him that require disclosure. A press release dated February 2, 2026, announcing his election, is included as an exhibit.
Encompass Health Corp reported an equity award to director Cain A. Hayes. On January 30, 2026, Hayes received 457 shares of Encompass Health common stock at a price of $0 per share, granted as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan. Following this award, Hayes directly beneficially owns 457 shares of Encompass Health common stock.